Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The management team will present on January 10, 2022, at 7:00 AM ET. A webcast of the presentation will be accessible on Savara’s website and archived for 90 days. The company focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on January 10, 2022 on Savara’s website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005183/en/

Savara Inc. IR & PR

Anne Erickson

Senior Vice President, Chief of Staff

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

When will Savara Inc. present at the H.C. Wainwright BIOCONNECT Virtual Conference?

Savara Inc. will present on January 10, 2022, at 7:00 AM ET.

Where can I watch the Savara Inc. presentation from the conference?

The presentation will be available on Savara's website and archived for 90 days.

What is Savara Inc. focusing on in its clinical development?

Savara Inc. is focused on developing treatments for rare respiratory diseases.

What is the lead program of Savara Inc.?

Savara's lead program is the molgramostim nebulizer solution for autoimmune pulmonary alveolar proteinosis (aPAP).

What phase is the molgramostim nebulizer solution currently in?

The molgramostim nebulizer solution is in Phase 3 development.